TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 75.3% in February

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 128,000 shares, a growth of 75.3% from the January 31st total of 73,000 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 41,000 shares, the days-to-cover ratio is presently 3.1 days.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TLSI shares. Cantor Fitzgerald started coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price target for the company. Roth Mkm reiterated a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Canaccord Genuity Group dropped their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Roth Capital raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday, November 11th. Finally, Lake Street Capital assumed coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They set a "buy" rating and a $10.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, TriSalus Life Sciences presently has an average rating of "Buy" and a consensus target price of $11.56.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, insider Sean Murphy purchased 15,000 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the completion of the purchase, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This represents a 8.94 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Equity Ab Frankenius acquired 62,972 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average cost of $3.97 per share, with a total value of $249,998.84. Following the purchase, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This represents a 1.02 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 117,828 shares of company stock valued at $544,607. 32.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after purchasing an additional 3,710 shares during the last quarter. Bank of America Corp DE grew its position in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after buying an additional 178,298 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after buying an additional 50,000 shares during the period. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the 3rd quarter worth $184,000. Finally, Northern Trust Corp lifted its stake in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the period. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Trading Down 1.0 %

Shares of NASDAQ TLSI traded down $0.06 during mid-day trading on Tuesday, reaching $5.60. The company had a trading volume of 15,190 shares, compared to its average volume of 33,098. The firm has a 50 day simple moving average of $5.22 and a two-hundred day simple moving average of $4.72. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42. The stock has a market cap of $170.61 million, a P/E ratio of -2.25 and a beta of 0.51.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.